Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe
Two biosimilar rituximab products have been recommended for approval in Europe, as has inotuzumab ozogamicin for acute lymphoblastic leukemia.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Hematology | Leukemia | Rituxan